Valuation: Norda ASA

Market Cap 513M 55.23M 47.29M 44.2M 40.45M 75.85M 5.28B 77.13M 522M 204M 2.65B 207M 203M 8.73B P/E 2023 *
-
P/E 2024 3.26x
Enterprise Value 264M 28.45M 24.36M 22.77M 20.84M 39.07M 2.72B 39.73M 269M 105M 1.37B 107M 104M 4.5B EV / Sales 2023
-1.24x
EV / Sales 2024 0.4x
Free-Float
6.26%
Yield 2023 *
-
Yield 2024 32.5%
Manager TitleAgeSince
Chief Executive Officer - 07/04/2013
Director TitleAgeSince
Chairman 54 30/01/2014
Director/Board Member 68 19/06/2013
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
+3.37%-6.12% - - 47.66M
-0.74%+4.48%+3.74%+22.46% 51.61B
+1.01%+3.86%+471.68%+577.49% 44.89B
+0.16%+9.96%+36.14%+20.40% 42.77B
-0.66%+7.05%+18.59%+83.42% 42.58B
+0.88%-3.48%+17.20%+57.20% 31.82B
-0.12%+7.18%+33.73%+148.24% 17.33B
-0.53%+1.39% - - 16.63B
+0.58%+4.00%+7.17%+30.59% 14.76B
+1.15%+6.62%+84.49%+47.81% 14.09B
Average +0.51%+4.83%+84.09%+123.45% 30.72B
Weighted average by Cap. +0.10%+5.13%+100.58%+142.48%

Financials

2023 2024
Net sales 86.92M 9.35M 8.01M 7.49M 6.85M 12.85M 895M 13.06M 88.49M 34.48M 449M 35.1M 34.34M 1.48B 372M 40.02M 34.26M 32.03M 29.31M 54.96M 3.83B 55.89M 379M 147M 1.92B 150M 147M 6.33B
Net income 31.17M 3.35M 2.87M 2.68M 2.46M 4.61M 321M 4.69M 31.74M 12.36M 161M 12.59M 12.32M 530M 126M 13.55M 11.61M 10.85M 9.93M 18.62M 1.3B 18.93M 128M 49.95M 651M 50.86M 49.76M 2.14B
Net Debt -311M -33.5M -28.68M -26.81M -24.53M -46M -3.21B -46.78M -317M -123M -1.61B -126M -123M -5.3B -249M -26.78M -22.93M -21.43M -19.61M -36.78M -2.56B -37.4M -253M -98.69M -1.29B -100M -98.3M -4.23B
Logo Norda ASA
Norda ASA, formerly NorDiag ASA, is a Norway-based company active within the biotechnology sector. It develops, manufactures and markets automated solutions (instruments and tests) for sample preparation of bacterial and human DNA from difficult biological samples for use in the fields of infectious diseases, transplantation testing (HLA Typing) and others. The Company’s products include NorDiag Arrow (CE, IVD), which is a compact, automated solution for nucleic acid extractions, as well as NorDiag Bullet, 8 tip config, which is a fully automated sample preparation instrument for molecular diagnostics and can isolate from samples such as urine, swab, faces, sputum and blood. Its distribution products include Molzym GmbH and Co KG, as well as Hain Lifescience GmbH. Its customers are clinical laboratories, hospitals, research institutes, medical diagnostics and healthcare providers. It is operational through offices and laboratories in Norway, Sweden, Austria and the United States.
Employees
-